[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623148":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":11,"centralContacts":49,"locations":55,"responsibleParty":92,"collaborators":11,"id":94,"slug":95,"hasResults":96,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":11,"eligibilityCriteria":100,"healthyVolunteers":96,"sex":101,"minAge":102,"maxAge":103,"enrollmentInfo":104,"targetDuration":11,"studyType":107,"phases":108,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":117,"whyStopped":11,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":127},{"fullName":5,"class":6},"Nanjing Sanhome Pharmaceutical, Co., Ltd.","INDUSTRY",[8,17,20,23],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm 1 SH006 in combination with bevacizumab and chemotherapy","EXPERIMENTAL",null,[13,14,15,16],"Drug: SH006","Drug: Bevacizumab","Drug: Oxaliplatin injection","Drug: Capecitabine",{"label":18,"type":10,"description":11,"interventionNames":19},"Arm 2 SH006 in combination with bevacizumab",[13,14],{"label":21,"type":10,"description":11,"interventionNames":22},"Arm 3 SH006 in combination with chemotherapy",[13,15,16],{"label":24,"type":25,"description":11,"interventionNames":26},"Arm 4 Regorafenib","ACTIVE_COMPARATOR",[27],"Drug: Regorafenib",[29,34,37,41,45],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":11},"DRUG","SH006","15 mg\u002Fkg administered as IV infusion on Day 1 of each 21-day cycle",[9,18,21],{"type":30,"name":35,"description":32,"armGroupLabels":36,"otherNames":11},"Bevacizumab",[9,18],{"type":30,"name":38,"description":39,"armGroupLabels":40,"otherNames":11},"Oxaliplatin injection","85 mg\u002Fm2 administered as IV infusion on Day 1 of each 21-day cycle",[9,21],{"type":30,"name":42,"description":43,"armGroupLabels":44,"otherNames":11},"Capecitabine","1000 mg\u002Fm2 orally twice daily for 14 days continuous dosing followed by a 7-day break of each 21-day cycle",[9,21],{"type":30,"name":46,"description":47,"armGroupLabels":48,"otherNames":11},"Regorafenib","160 mg orally once daily for 21 days continuous dosing followed by a 7-day break of each 28-day cycle",[24],[50],{"name":51,"role":52,"phone":53,"phoneExt":11,"email":54},"Jie Min","CONTACT","86-15121121360","minjie@sanhome.com",[56,76],{"facility":57,"status":11,"city":58,"state":59,"zip":60,"country":61,"countryCode":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":69},"Nanjing Tianyinshan Hospital","Nanjing","Jiangsu","211199","China","CN",{"type":64,"coordinates":65},"Point",[66,67],118.77778,32.06167,{"lat":67,"lon":66},[70,74],{"name":71,"role":52,"phone":72,"phoneExt":11,"email":73},"Shukui Qin","86-13905158713","qinsk81@163.com",{"name":71,"role":75,"phone":11,"phoneExt":11,"email":11},"PRINCIPAL_INVESTIGATOR",{"facility":77,"status":11,"city":78,"state":79,"zip":80,"country":61,"countryCode":62,"cosmosGeoPoint":81,"geoPoint":85,"contacts":86},"Zhongshan Hospital, Fudan University","Shanghai","Shanghai Municipality","200032",{"type":64,"coordinates":82},[83,84],121.45806,31.22222,{"lat":84,"lon":83},[87,91],{"name":88,"role":52,"phone":89,"phoneExt":11,"email":90},"Jian Zhou","86-13801914007","zhou.jian@zs-hospital.sh.cn",{"name":88,"role":75,"phone":11,"phoneExt":11,"email":11},{"type":93,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100623148","phase-2-a-clinical-study-of-sh006-injection-in-combination-therapy-versus-regorafenib-in-the-treatment-of-advanced-hepatocellular-carcinoma-100623148",false,"NCT07392866","A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma","A Prospective, Randomized, Active-Controlled, Open-Label, National Multicenter Phase II\u002FIII Registration Study of SH006 Injection Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma","Inclusion Criteria:\n\n* Subjects participate voluntarily and sign informed consent.\n* Age ≥ 18 and ≤ 75 years old, male or female.\n* Histological or clinical diagnosis of HCC.\n* Barcelona Clinic Liver Cancer stage C. BCLC stage B, not suitable for radical surgery and\u002For local treatment\n* Previous treatment with a drug containing an immune checkpoint inhibitor failed.\n* Child-Pugh ≤7 , no history of hepatic encephalopathy.\n\nExclusion Criteria:\n\n* Histologically documented fibrolamellar hepatocellular carcinoma, sarcoma-like hepatocellular carcinoma, etc.\n* History of malignancy other than HCC within 5 years prior to the start of study treatment.\n* History of liver transplantation, or planned to receive liver transplantation.\n* Moderate or severe ascites with clinical symptoms that require drainage, uncontrolled or moderate or severe pleural and pericardical effusion.\n* Has known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis.\n* Involvement of both the main portal vein and the left and right branches by portal vein tumor thrombus, or of both the main trunk and the superior mesenteric vein concurrently, or of inferior vena cava.","ALL","18 Years","75 Years",{"count":105,"type":106},120,"ESTIMATED","INTERVENTIONAL",[109,110],"PHASE2","PHASE3","To evaluate the efficacy and safety of the combination therapy of SH006 injection in the treatment of advanced hepatocellular carcinoma",[113],"Hepatocellular Carcinoma (HCC)",[115,116],"hepatocellular carcinoma","immune checkpoint inhibitors","NOT_YET_RECRUITING","2026-02-05",{"date":120,"type":121},"2026-02-09","ACTUAL",{"date":123,"type":106},"2026-03-01",{"date":125,"type":106},"2030-03-01",{"name":5,"class":6},2]